GNH USA

Europe — EMA

Octaplasmalg (Ab) (Human Plasma Protein)

GNH USA supplies Octaplasmalg (Ab) (Human Plasma Protein), a plasma‑derived protein therapy for hemostasis and coagulation support.

Human Plasma Protein

Request sourcing

1
Pack/s

What is Human Plasma Protein?

Human Plasma Protein, the active ingredient in Octaplasmalg (Ab), is a plasma‑derived protein therapy presented as a sterile liquid for intravenous use. It is employed to support hemostasis in patients with acquired or congenital deficiencies of plasma proteins.

GNH USA supplies Octaplasmalg (Ab) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Human Plasma Protein used for?

Octaplasmalg (Ab) is used within the plasma‑protein replacement and hemostasis therapeutic pathway. - Bleeding due to coagulation factor deficiency: provides a broad spectrum of clotting factors to restore normal hemostasis. - Massive transfusion protocols: replenishes plasma proteins lost during large‑volume blood product administration. - Liver disease‑related coagulopathy: supplies deficient clotting factors to improve coagulation balance.

What are the side effects of Human Plasma Protein?

Octaplasmalg (Ab) may be associated with a range of adverse reactions.

Common Side Effects: - Mild fever or chills - Transient hypotension - Headache - Nausea or vomiting - Local infusion site erythema - Mild allergic rash

Serious or Rare Side Effects: - Anaphylactic reaction - Acute hemolytic transfusion reaction - Transfusion‑related acute lung injury (TRALI) - Severe thrombosis or embolism - Viral transmission (theoretical risk) - Severe electrolyte imbalance

What precautions apply to Human Plasma Protein?

Octaplasmalg (Ab) requires careful clinical monitoring and adherence to safety guidelines. - Patient assessment: evaluate coagulation status and plasma protein levels before infusion. - Infusion rate: administer slowly to reduce risk of hypotension or allergic reactions. - Volume overload: monitor fluid balance in patients with cardiac or renal impairment. - Compatibility: verify compatibility with other blood products and avoid mixing with incompatible solutions. - Contraindications: do not use in patients with known hypersensitivity to plasma proteins. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Human Plasma Protein interact with?

Octaplasmalg (Ab) can interact with other agents that affect coagulation or immune response.

Major Interactions (Avoid): - Concurrent use of high‑dose anticoagulants (e.g., warfarin, heparin) may exacerbate bleeding risk. - Administration with other plasma‑derived products can increase volume overload risk.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., corticosteroids) may mask allergic signs. - Diuretics may potentiate fluid shifts when large volumes are infused. - ACE inhibitors can augment hypotensive episodes during rapid infusion.

Frequently asked questions

What is Octaplasmalg (Ab) used for?+
Octaplasmalg (Ab) is a plasma‑derived protein therapy used to replace deficient clotting factors and support hemostasis in conditions such as bleeding disorders, massive transfusion scenarios, and coagulopathy associated with liver disease. It provides a broad spectrum of plasma proteins to help restore normal clotting function.
How does Human Plasma Protein work in the body?+
Human Plasma Protein contains a balanced mix of clotting factors, albumin, and immunoglobulins. When infused, it expands plasma volume and directly replaces missing or reduced clotting proteins, thereby enhancing both the intrinsic and extrinsic pathways of the coagulation cascade and promoting effective blood clot formation.
What is the usual dose of Octaplasmalg (Ab)?+
The dosage of Octaplasmalg (Ab) is individualized and determined by the prescribing clinician based on the patient’s specific clinical condition, weight, coagulation profile, and the extent of plasma protein deficiency. Healthcare professionals calculate the appropriate volume to achieve the desired therapeutic effect.
Is Octaplasmalg (Ab) safe during pregnancy or breastfeeding?+
Safety data for Octaplasmalg (Ab) in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the treating physician. The potential benefits of correcting a serious coagulation disorder must outweigh any theoretical risks to the fetus or infant.
How do I order Octaplasmalg (Ab) from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.
How does Octaplasmalg (Ab) compare with other plasma‑derived therapies?+
Octaplasmalg (Ab) offers a standardized, pathogen‑reduced plasma protein preparation that provides a broad spectrum of clotting factors, similar to other plasma‑derived concentrates. Compared with single‑factor concentrates, it can address multiple deficiencies simultaneously, but clinicians may choose specific factor products when a single deficiency is identified.
What are the storage and handling requirements for Octaplasmalg (Ab)?+
Octaplasmalg (Ab) must be stored at 2‑8 °C, protected from light, and kept in its original container. It should not be frozen or shaken. Prior to administration, inspect the product for any discoloration or particulate matter and allow it to reach room temperature if required by the infusion protocol.
How is Octaplasmalg (Ab) administered?+
Octaplasmalg (Ab) is administered intravenously under the supervision of qualified healthcare personnel. The infusion rate is typically controlled to minimize adverse reactions, and patients are monitored for vital signs and any signs of hypersensitivity throughout the administration.
What are the most serious risks associated with Octaplasmalg (Ab)?+
Serious risks include anaphylactic reactions, transfusion‑related acute lung injury (TRALI), acute hemolytic transfusion reactions, severe thrombosis, and the theoretical risk of viral transmission despite rigorous pathogen reduction processes. Prompt recognition and management of these events are essential.
Who should not receive Octaplasmalg (Ab)?+
Octaplasmalg (Ab) is contraindicated in individuals with a known hypersensitivity to human plasma proteins or any of the product’s excipients. It should also be avoided in patients with uncontrolled volume overload, severe cardiac failure, or those who have experienced prior severe transfusion reactions.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Human Plasma Protein
Route
Intravenous Use
Manufacturer
Octapharma S.A.
Origin
EU

Related products

Albiomin

Albiomin

Human Plasma Protein

Biotest Pharma Gmbh
EU
Albumeon

Albumeon

Human Plasma Protein

Csl Behring Gmbh
EU
Albumeon

Albumeon

Human Plasma Protein

Csl Behring Gmbh
EU
Albumeon

Albumeon

Human Plasma Protein

Csl Behring E.P.E.
EU